USD0.000æéå€ååŒÂ  (ET)
20.24BæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
163.450å§å€
176.580é«å€
4.58Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
3.67%売買å転ç
152.350忥çµå€
160.010å®å€
547.23M売買代é
æå€±é¡æ ªäŸ¡åçç
-57.11PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-26.58%ç·è³ç£å©çç
133.70552é±é«å€
2.24åºæ¥é«æ¯ç%
-436.37MçŽå©ç
125.01Mæ ªåŒæ°
-3.40581æ ªåœããå©çïŒEPSïŒ
1.60ããŒã¿å€
-4584.47%èªå·±è³æ¬å©çç
38.03052é±å®å€
10.88%æ¯ãå¹
65.39%ç²å©çç
20.24BæäŸ¡ç·é¡
-3.07ãªã¹ã¯ãªã¿ãŒã³
3.03%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Guardant Health Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»çæ©åš & å忥çã§ã®é äœã¯199äž12äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯169.10ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Guardant Health Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Guardant Health Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Guardant Health Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Zimmer Biomet Holdings Inc
ZBH
31
ææšî
ææš
売ã(1)
äžç«(2)
è²·ã(4)
ç§»åå¹³å
売ã(0)
äžç«(0)
è²·ã(6)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Guardant Health Incã®äŒæ¥æ
å ±î
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
äŒæ¥ã³ãŒãGH
äŒæ¥åGuardant Health Inc
æé«çµå¶è²¬ä»»è
ãCEOãTalasaz (Amirali)
ãŠã§ããµã€ãhttps://guardanthealth.com/
æ ªäž»çµ±èšî
ãããã質å
Guardant Health IncïŒGHïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îGuardant Health IncïŒGHïŒã®çŸåšã®æ ªäŸ¡ã¯161.95ã§ãã
Guardant Health Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îGuardant Health Incã®ãã£ãã«ãŒã·ã³ãã«ã¯GHã§ãã
Guardant Health Incã®52é±é«å€ã¯ãããã§ããïŒ
îGuardant Health Incã®52é±é«å€ã¯133.71ã§ãã
Guardant Health Incã®52é±å®å€ã¯ãããã§ããïŒ
îGuardant Health Incã®52é±å®å€ã¯38.03ã§ãã
Guardant Health Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îGuardant Health Incã®æäŸ¡ç·é¡ã¯20.24Bã§ãã
Guardant Health Inc (GH) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãGuardant Health IncïŒGHïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯169.10ã§ãã
Guardant Health Inc (GH) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îGuardant Health IncïŒGHïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-3.32ã§ãã